Bimatoprost

比马前列素
  • 文章类型: Journal Article
    由于许多因素导致的黑素细胞的丢失和缺失是白癜风的原因;已知是最常见的色素沉着障碍。目前的工作的目的是比较准分子光与局部他克莫司软膏0.1%与准分子光与局部比马前列素凝胶0.01%治疗面部白癜风的疗效和安全性。这项研究是对48例面部白癜风患者进行的。采用密封信封法将患者随机分为两组(每组24例)。第1组采用准分子光加0.1%的他克莫司软膏治疗,第2组采用准分子光加0.01%的比马前列素凝胶治疗。治疗结束时基于四分位数分级量表的临床改善在组间没有任何统计学上的显著差异。两组中的大多数受试者都经历了良好到出色的改善。在第1组中只有20.9%的患者和第2组中33.3%的受试者实现了小于50%的再色素沉着(p=0.889)。我们的研究表明,0.01%的局部比马前列素凝胶与准分子光联合治疗非节段面部白癜风被认为是安全有效的,其结果与0.1%他克莫司相当。
    Loss and absence of melanocytes due to a number of factors is responsible for vitiligo; known to be the commonest disorder of pigmentation. The aim of the current work was to compare the efficacy and safety of excimer light with topical tacrolimus ointment 0.1% versus excimer light with topical bimatoprost gel 0.01% in treatment of facial vitiligo. The study was carried out on 48 patients presented with facial vitiligo. The patients were divided randomly using sealed envelope method into two groups (24 patients each). Group 1 were treated with excimer light plus topical tacrolimus ointment 0.1% and group 2 treated with excimer light plus topical bimatoprost gel 0.01%. Clinical improvement based on the quartile grading scale at the end of treatment did not show any statistically significant difference between groups. The majority of subjects in both groups experienced good to excellent improvement. Only 20.9% of patients in group 1 and 33.3% of subjects in group 2 achieved less than 50% repigmentation (p = 0.889). Our study demonstrated that 0.01% topical bimatoprost gel in combination with excimer light is considered safe and effective as treatment of nonsegmental facial vitiligo with comparable results to 0.1% tacrolimus.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:在过去的几十年中,比马前列素已成为医学领域的重要药物,在眼科的不同应用,皮肤病学,和超越。最初是作为一种降眼压剂开发的,它已被证明对治疗青光眼和高眼压症非常有效。其降低眼内压的能力已将其确立为一线治疗选择,改善管理,防止视力丧失。在皮肤科,比马前列素在促进头发生长方面显示出有希望的结果,特别是在治疗脱发和毛发减少症。其作用机制,刺激头发周期并延长生长期,导致了用于增强睫毛生长的含比马前列素的溶液的开发。
    目的:我们的审查的目的是提供一个简短的描述,概述,以及近年来有关比马前列素的广泛临床应用的现有文献研究。这可以帮助临床医生确定最合适的个性化治疗,以满足每个患者的需求。
    方法:我们的方法包括对文献中报道的比马前列素制剂的最新进展的全面回顾,从传统的滴眼液到缓释植入物。这些创新提供了延长的药物输送,提高患者依从性,尽量减少副作用。
    结果:在PubMed上发表的大量文献证实了比马前列素在降低眼压和治疗青光眼患者方面的临床有效性。许多研究已经在皮肤病学和美学方面显示了促进头发生长的有希望的结果,特别是在治疗脱发和毛发减少症。其作用机制涉及刺激头发周期和延长生长期,导致促进睫毛生长的解决方案的开发。比马前列素的全球使用已显著扩大,随着应用的增长超出了最初的迹象。正在进行的研究正在探索其在青光眼手术中的潜力,神经保护,和美容程序。
    结论:比马前列素已显示出通过各种配方和改进满足广泛治疗需求的巨大潜力。有希望的未来前景包括探索新型递送系统,如隐形眼镜和微针,以进一步提高药物疗效和患者舒适度。正在进行的研究和未来的观点继续塑造其在医学中的作用,有希望的进一步进步和改善患者的结果。
    BACKGROUND: Bimatoprost has emerged as a significant medication in the field of medicine over the past several decades, with diverse applications in ophthalmology, dermatology, and beyond. Originally developed as an ocular hypotensive agent, it has proven highly effective in treating glaucoma and ocular hypertension. Its ability to reduce intraocular pressure has established it as a first-line treatment option, improving management and preventing vision loss. In dermatology, bimatoprost has shown promising results in the promotion of hair growth, particularly in the treatment of alopecia and hypotrichosis. Its mechanism of action, stimulating the hair cycle and prolonging the growth phase, has led to the development of bimatoprost-containing solutions for enhancing eyelash growth.
    OBJECTIVE: The aim of our review is to provide a brief description, overview, and studies in the current literature regarding the versatile clinical use of bimatoprost in recent years. This can help clinicians determine the most suitable individualized therapy to meet the needs of each patient.
    METHODS: Our methods involve a comprehensive review of the latest advancements reported in the literature in bimatoprost formulations, which range from traditional eye drops to sustained-release implants. These innovations offer extended drug delivery, enhance patient compliance, and minimize side effects.
    RESULTS: The vast literature published on PubMed has confirmed the clinical usefulness of bimatoprost in lowering intraocular pressure and in managing patients with glaucoma. Numerous studies have shown promising results in dermatology and esthetics in promoting hair growth, particularly in treating alopecia and hypotrichosis. Its mechanism of action involves stimulating the hair cycle and prolonging the growth phase, leading to the development of solutions that enhance eyelash growth. The global use of bimatoprost has expanded significantly, with applications growing beyond its initial indications. Ongoing research is exploring its potential in glaucoma surgery, neuroprotection, and cosmetic procedures.
    CONCLUSIONS: Bimatoprost has shown immense potential for addressing a wide range of therapeutic needs through various formulations and advancements. Promising future perspectives include the exploration of novel delivery systems such as contact lenses and microneedles to further enhance drug efficacy and patient comfort. Ongoing research and future perspectives continue to shape its role in medicine, promising further advancements and improved patient outcomes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    目的:本病例报告旨在报告双眼注射比马前列素植入物(Durysta)治疗原发性开角型青光眼(POAG)后单侧出现囊样黄斑水肿(CME)。
    方法:一名84岁女性患者,以前被诊断患有POAG,双眼接受比马前列素植入(Durysta)注射,相隔一个月。随后,由于CME的发展,患者的左眼视力逐渐下降。在涉及局部地塞米松和奈帕芬胺的治疗方案后,病情得以解决。
    结论:使用比马前列素植入物可能导致CME的发生。眼科医生必须警惕地监测植入后的患者,特别是如果他们表现出视觉症状或有CME的危险因素。
    OBJECTIVE: This case report aims to report the development of cystoid macular edema (CME) unilaterally following the administration of bimatoprost implant (Durysta) injections in both eyes for the treatment of primary open-angle glaucoma (POAG).
    METHODS: An 84-year-old female patient, previously diagnosed with POAG, underwent bimatoprost implant (Durysta) injections in both eyes, spaced one month apart. Subsequently, the patient experienced a gradual decline in visual acuity in her left eye attributed to the development of CME. The condition resolved following a treatment regimen involving topical dexamethasone and nepafenac.
    CONCLUSIONS: The use of bimatoprost implant may lead to the occurrence of CME. Ophthalmologists must vigilantly monitor patients post-implantation, especially if they exhibit visual symptoms or have risk factors for a CME.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    比马前列素(BIM)是最初被批准用于治疗青光眼和高眼压症的前列腺素F2α类似物。最近的研究强调了它促进头发生长的潜力。这项研究的目的是挑战作为基于表面活性剂的囊泡系统促进BIM皮肤输送以治疗脱发的潜力。BIM加载的asanlasics(BIM-SL),由Span作为主要囊泡成分和Tween作为边缘激活剂组成,采用乙醇注射法制备。通过23个全因子设计对配方BIM-SL进行了优化。对优化配方(F1)的包封率进行了表征,表面电荷,囊泡大小,和药物释放后12h(Q12h)。优化配方(F1)具有较高的药物包封率(83.1±2.1%),适当的zeta电位(-19.9±2.1mV),Q12h为71.3±5.3%,囊泡尺寸为364.2±15.8nm,这有利于它们的皮肤积累。此外,体外皮肤沉积研究表明,将BIM包埋在基于弹性的纳米凝胶(BIM-SLG)中可增强BIM的皮肤沉积,与幼稚的BIM凝胶相比。此外,体内研究证实,与原始BIM凝胶相比,弹性囊泡促进BIM皮肤积聚的功效;BIM-SLG的AUC0-12h为888.05±72.31μg/mL。h,这是初始BIM凝胶的两倍(AUC0-12h382.86±41.12μg/mL。h).有趣的是,BIM-SLG在刺激雄激素性脱发小鼠模型中的毛发再生方面优于原始BIM凝胶和商业米诺地尔制剂。总的来说,在治疗脱发时,弹性囊泡可能是促进BIM皮肤递送的潜在平台。
    Bimatoprost (BIM) is a prostaglandin F2α analogs originally approved for the treatment of glaucoma and ocular hypertension. Recent studies have highlighted its potential to boost hair growth. The objective of this investigation is to challenge the potential of spanlastics (SLs) as a surfactant-based vesicular system for promoting the cutaneous delivery of BIM for the management of alopecia. BIM-loaded spanlastics (BIM-SLs), composed of Span as the main vesicle component and Tween as the edge activator, were fabricated by ethanol injection method. The formulated BIM-SLs were optimized by 23 full factorial design. The optimized formula (F1) was characterized for entrapment efficiency, surface charge, vesicle size, and drug release after 12 h (Q12h). The optimized formula (F1) exhibited high drug entrapment efficiency (83.1 ± 2.1%), appropriate zeta potential (-19.9 ± 2.1 mV), Q12h of 71.3 ± 5.3%, and a vesicle size of 364.2 ± 15.8 nm, which favored their cutaneous accumulation. In addition, ex-vivo skin deposition studies revealed that entrapping BIM within spanlastic-based nanogel (BIM-SLG) augmented the dermal deposition of BIM, compared to naïve BIM gel. Furthermore, in vivo studies verified the efficacy of spanlastic vesicles to boost the cutaneous accumulation of BIM compared to naive BIM gel; the AUC0-12h of BIM-SLG was 888.05 ± 72.31 μg/mL.h, which was twice as high as that of naïve BIM gel (AUC0-12h 382.86 ± 41.12 μg/mL.h). Intriguingly, BIM-SLG outperforms both naïve BIM gel and commercial minoxidil formulations in stimulating hair regrowth in an androgenetic alopecia mouse model. Collectively, spanlastic vesicles might be a potential platform for promoting the dermal delivery of BIM in managing alopecia.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    结论:在杜克眼科中心接受比马前列素植入的青光眼患者的回顾性研究中,植入后12个月,局部用降低眼压药物的数量显著减少.
    目的:在临床实践中,研究比马前列素植入物对青光眼患者眼内压(IOP)的影响以及对局部降眼压药物的需求。
    方法:确定了2020年11月至2021年10月在杜克大学眼科中心接受比马前列素植入的患者。排除标准包括与植入物同时添加其他降低IOP的药物和<1个月的随访。计算植入物后从基线到第1、3、6、9和12个月的IOP变化和局部降低IOP的药物数量。对不同严重程度的青光眼进行亚组分析。
    结果:共纳入63例患者和92只眼(平均年龄77.8±10.1岁)。青光眼严重程度从轻度(11%),中等(30%),严重(54%)。所有时间点的IOP均无显著下降。在第1、3、6、9和12个月,局部降眼压药物的平均数量分别显着减少了0.81、0.75、0.63、0.70和0.67(均P<0.001)。药物总数没有显著变化,包括比马前列素植入物.当除以青光眼严重程度时,轻度/中度疾病在1个月,3个月和6个月时局部用药数量显著减少,重度疾病在1个月时局部用药数量显著减少.在后续期间,19只眼睛接受了额外的激光或外科手术,其中68%有切口性青光眼手术史。
    结论:比马前列素植入物可在1年内减少局部降眼压药物的需要,尤其是轻度至中度青光眼。在严重的青光眼中,植入物的功效可能更有限,需要进一步的工作来表征其长期影响。
    CONCLUSIONS: In this retrospective study of glaucoma patients receiving the bimatoprost implant at Duke Eye Center, the number of topical intraocular pressure-lowering medications was significantly reduced through 12 months after the implant.
    OBJECTIVE: To study the effects of the bimatoprost implant on intraocular pressure (IOP) and the need for topical IOP-lowering medications in glaucoma patients in the clinical practice setting.
    METHODS: Patients who received the bimatoprost implant at Duke Eye Center from November 2020 to October 2021 were identified. Exclusion criteria included addition of other IOP-lowering medications concurrent with the implant and <1 month of follow-up. The change in IOP and number of topical IOP-lowering medications from baseline to months 1, 3, 6, 9, and 12 after the implant was calculated. Subgroup analysis was performed for different glaucoma severities.
    RESULTS: A total of 63 patients and 92 eyes were included (mean age 77.8 ± 10.1 years). Glaucoma severity ranged from mild (11%), moderate (30%), to severe (54%). There was a nonsignificant decrease in IOP at all timepoints. The mean number of topical IOP-lowering medications significantly decreased by 0.81, 0.75, 0.63, 0.70, and 0.67 at month 1, 3, 6, 9, and 12, respectively (all P < 0.001). There was no significant change in the total number of medications, including the bimatoprost implant. When divided by glaucoma severity, the reduction in the number of topical medications was significant at 1, 3, and 6 months for mild/moderate disease and at 1 month for severe disease. During the follow-up period, 19 eyes underwent additional laser or surgical procedures, 68% of which had a history of prior incisional glaucoma surgery.
    CONCLUSIONS: The bimatoprost implant may reduce the need for topical IOP-lowering agents over a 1-year period, especially in mild to moderate-stage glaucoma. The efficacy of the implant may be more limited in severe glaucoma, and further work is needed to characterize its long-term effects.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    结论:在开角型青光眼或高眼压症患者治疗12周后,与含BAK的比马前列素0.01%相比,无防腐剂的比马前列素0.01%的疗效无劣性。提高耐受性,特别是结膜充血,也被观察到了。
    目的:评价不含防腐剂的0.01%比马前列素眼用凝胶(PFB0.01%凝胶)与保存的0.01%比马前列素(PB0.01%)相比,降低眼压(IOP)的疗效和安全性。
    方法:第三阶段,国际,多中心,随机化,2平行组,调查员-蒙面,3个月的治疗时间。
    方法:患有青光眼或高眼压的患者在7周的磨合/冲洗期后随机接受每日一次的0.01%PFB凝胶(n=236)或0.01%PB(n=249),持续3个月。在第12周,主要疗效指标从IOP的基线变化。安全性措施包括不良事件(AE)和结膜充血的评估。
    结果:PFB0.01%凝胶和PB0.01%凝胶在12周时IOP相对于基线的平均变化分别为-9.72±2.97和-9.47±3.06mmHg,分别,早上8点,上午10点-9.41±3.03和-9.19±3.12mmHg,下午4点-8.99±3.36和-8.54±3.44mmHg。基于预定标准(在所有时间点均为1.5mmHg的95%CI上限),在第12周证明PFB0.01%凝胶对PB0.01%的非劣效性。最常见的AE是结膜充血;13例(5.5%)患者为PFB0.01%凝胶,17例(6.8%)患者为PB0.01%。与第6周的PB0.01%相比,PFB0.01%凝胶的结膜充血评分从基线恶化的患者百分比较低(20.1%vs.29.3%,分别)和第12周(18.3%与30.4%,分别)。
    结论:0.01%PFB眼用凝胶在降低IOP方面具有与0.01%PB相同的功效,并且在第6周和第12周时结膜充血的加重较少。
    CONCLUSIONS: Noninferiority of efficacy was demonstrated for a preservative-free bimatoprost 0.01% compared with BAK-containing bimatoprost 0.01% following a 12-week treatment period in patients with open angle glaucoma or ocular hypertension. Improved tolerability, in particular conjunctival hyperemia, was also observed.
    OBJECTIVE: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of a preservative-free bimatoprost 0.01% ophthalmic gel (PFB 0.01% gel) compared with preserved bimatoprost 0.01% (PB 0.01%).
    METHODS: Phase III, international, multicenter, randomized, 2-parallel group, investigator-masked, 3-month treatment duration.
    METHODS: Patients with glaucoma or ocular hypertension were randomized after a 7-week run-in/washout period to receive once-daily PFB 0.01% gel (n=236) or PB 0.01% (n=249) for 3 months. The primary efficacy measure was changed from baseline in IOP at week 12. Safety measures included adverse events (AEs) and assessment of conjunctival hyperemia.
    RESULTS: The mean changes from baseline in IOP at week 12 in the PFB 0.01% gel and PB 0.01% were -9.72±2.97 and -9.47±3.06 mm Hg, respectively, at 8 am , -9.41±3.03 and -9.19±3.12 mm Hg at 10 am , and -8.99±3.36 and -8.54±3.44 mm Hg at 4 pm . Noninferiority of PFB 0.01% gel to PB 0.01% was demonstrated at week 12 based on predetermined criteria (upper 95% CI margin of 1.5 mmHg at all time points). The most frequently reported AE was conjunctival hyperemia; 13 (5.5%) patients with PFB 0.01% gel and 17 (6.8%) patients with PB 0.01%. The percentage of patients experiencing a worsening from baseline in conjunctival hyperemia score was lower with PFB 0.01% gel compared to PB 0.01% at week 6 (20.1% vs. 29.3%, respectively) and week 12 (18.3% vs. 30.4%, respectively).
    CONCLUSIONS: PFB 0.01% ophthalmic gel has the same efficacy in lowering IOP as PB 0.01% and demonstrated less aggravation of conjunctival hyperemia at weeks 6 and 12.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:比较提供一氧化氮(NO)的比马前列素NCX470降低眼压(IOP)的疗效和安全性,拉坦前列素对青光眼或高眼压患者的影响。
    方法:前瞻性,第三阶段,随机,自适应剂量选择,双面蒙面,平行组试验。
    方法:参与者:691名患有开角型青光眼或高眼压且8AM时IOP≥26mmHg的未用药IOP的受试者,上午10点≥24mmHg,研究眼下午4点≥22mmHg。研究程序:受试者随机接受NCX4700.065%治疗,NCX4700.1%,或拉坦前列素0.005%。为了确定最终的NCX470剂量,在每组至少30名受试者完成第2周访视后进行中期分析.注册的受试者被随机分配到最终的NCX470剂量,0.1%,或拉坦前列素12周.
    方法:我们评估了NCX470与拉坦前列素的非劣效性,基于2周时8AM和4PM从基线降低的IOP,6周,和3个月。
    结果:最终剂量为NCX4700.1%,分析了661名接受NCX4700.1%(n=328)或拉坦前列素(n=333)的受试者。在基线,上午8点和下午4点的平均眼压(SD)分别为28.3(2.0)mmHg和25.5(2.5)mmHg,分别,在NCX4700.1%组中,并且在所有治疗时间点都显着减少,降低范围为8.0-9.7mmHg(每个时间点p<0.0001)。同样,8AM和4PM时的平均(SD)基线眼压为28.2(2.0)mmHg和25.4(2.4)mmHg,分别,在拉坦前列素组中,在所有治疗时间点均显着降低,降低范围为7.1-9.4mmHg(每个时间点p<0.0001)。在为期三个月的访问中,在所有6个时间点,NCX为4700.1%时的平均IOP下降幅度大于拉坦前列素0.005%,在6个时间点中的4个时间点时显著更大(p<.05).在所有6个时间点建立相对于拉坦前列素的非劣效性。最常见的不良事件是结膜/眼部充血,与拉坦前列素相比,NCX470组更为常见;8名NCX470和6名拉坦前列素受试者因不良事件而停药。
    结论:在所有6个时间点,在患有开角型青光眼或高眼压的受试者中,提供NO的前列腺素类似物NCX4700.1%具有良好的耐受性,并且比拉坦前列素降低了更多的IOP。具有双重作用机制,可增强葡萄膜巩膜和小梁流出,NCX470可能成为青光眼眼压降低的重要一线治疗方法。
    OBJECTIVE: To compare intraocular pressure (IOP)-lowering efficacy and safety of NCX 470, a nitric oxide (NO)-donating bimatoprost, to latanoprost in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
    METHODS: Prospective, phase 3, randomized, adaptive dose-selection, double-masked, parallel-group trial.
    METHODS: 691 subjects with OAG or OHT and unmedicated IOP ≥26 mmHg at 8AM, ≥24 mmHg at 10AM, and ≥22 mmHg at 4PM in the study eye were randomized to NCX 470 0.065%, NCX 470 0.1%, or latanoprost 0.005%. An interim analysis was performed to select the final dose of NCX 470. We evaluated noninferiority of NCX 470 versus latanoprost, based on IOP reduction from baseline at 8AM and 4PM at 2 weeks, 6 weeks, and 3 months.
    RESULTS: 661 subjects were analyzed; IOP was significantly reduced at all on-treatment time points, with reductions ranging from 8.0 to 9.7 mmHg (P < .0001 at each time point) in the NCX 470 0.1% group. Mean IOP reductions were greater with NCX 470 0.1% than latanoprost 0.005% at all 6 time points and significantly greater (P < .05) at 4 of the 6 time points. The most common adverse event was conjunctival/ocular hyperemia.
    CONCLUSIONS: The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with OAG or OHT at all 6 time points. With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important first-line therapy for IOP reduction in glaucoma.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:睫毛血清,处方药和非处方药,通过各种生物活性分子增强睫毛的外观越来越受欢迎。分为前列腺素类似物和非前列腺素类似物,这些血清声称强度增加,长度,光泽,和厚度。美国现行法律还要求在批准供消费者使用的产品之前,美国食品和药物管理局不进行任何功效或安全性评估。可能对寻求非处方睫毛增强的患者构成健康风险。
    目的:我们的目标包括探索与睫毛血清相关的拟议益处和不良反应,同时提供有关其使用的循证临床建议。我们的目标是为理解睫毛浆液及其各自的安全考虑提供有价值的见解。
    方法:作者对包括PubMed在内的数据库进行了全面的电子搜索,Embase,CochraneCentral,和谷歌学者评估睫毛血清成分。文章由两名独立研究人员评估相关性,和讨论的成分进行了分析,并给出了基于牛津循证医学中心的睫毛血清的临床建议。
    结果:结果突出显示比马前列素的疗效,由许多评估安全性和不良反应的研究支持。其他前列腺素成分显示出潜在的益处,但我们鼓励进一步研究,以加强对各自安全状况的了解。虽然非前列腺素成分显示出有希望的数据,由于缺乏睫毛血清使用的正式证据,需要更多的研究。
    结论:随着睫毛浆液的药妆市场的增长,在向患者提出建议之前,皮肤科医生需要了解有关处方和非处方睫毛血清产品的循证信息。
    BACKGROUND: Eyelash serums, both prescription and over-the-counter, are gaining popularity for enhancing the appearance of eyelashes through various biologically active molecules. Categorized into prostaglandin analogs and non-prostaglandin analogs, these serums claim increased strength, length, luster, and thickness. Current United States law also requires no efficacy or safety assessments by the Food and Drug Administration before approving products for consumer use, potentially posing health risks for patients seeking over-the-counter eyelash enhancements.
    OBJECTIVE: Our aims include exploring proposed benefits and adverse effects associated with eyelash serums, while providing evidence-based clinical recommendations on their use. We aim to contribute valuable insights to the understanding of eyelash serums and their respective safety considerations.
    METHODS: The authors conducted a comprehensive electronic search across databases including PubMed, Embase, Cochrane Central, and Google Scholar to evaluate eyelash serum ingredients. Articles were evaluated by two independent researchers for relevance, and the ingredients discussed were analyzed and given clinical recommendations for eyelash serums based off the Oxford Centre for Evidence-Based Medicine.
    RESULTS: Results highlight bimatoprost\'s efficacy, supported by numerous studies evaluating safety and adverse effects. Other prostaglandin ingredients show potential benefits, but further studies are encouraged to enhance the understanding of respective safety profiles. While non-prostaglandins ingredients show promising data, more studies are needed due to a lack of formal evidence in eyelash serum use.
    CONCLUSIONS: As the cosmeceutical market for eyelash serums is growing, dermatologists need to be knowledgeable about evidence-based information regarding prescription and over-the-counter eyelash serum products before making recommendations to patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    药物洗脱隐形眼镜(DECL)与聚(乳酸-乙醇酸共聚物)(PLGA)和各种模型药物(富马酸酮替芬,比马前列素和拉坦前列素)是使用纳米电喷雾(nES)方法制造的。所得的DECLs在光学区内表现出出色的光学透射率,表明在规定的喷涂参数下,采用的涂层程序不会损害视力。模型药物(富马酸酮替芬(KF),比马前列素(BIM),和拉坦前列素(LN))揭示了模型药物的疏水性与药物释放持续时间之间的强相关性。改变更亲水的模型药物的载药量,BIM和KF,显示对负载有BIM和KF的DECL的药物释放动力学没有影响。然而,对于疏水模型药物,LN,最高的LN负载导致最延长的药物释放。发现常规蒸汽灭菌方法会损坏nES制造的DECL上的PLGA涂层。另一种绝育策略,例如辐射消毒可能需要在未来的研究中进行研究,以尽量减少对涂层的潜在伤害。
    Drug-eluting contact lenses (DECLs) incorporated with poly(lactic-co-glycolic acid) (PLGA) and various model drugs (ketotifen fumarate, bimatoprost and latanoprost) were fabricated using nanoelectrospray (nES) approach. The resulting DECLs demonstrated outstanding optical transmittance within the optical zone, indicating that the employed coating procedure did not compromise visual acuity under the prescribed spraying parameters. In vitro drug release assessments of the model drugs (ketotifen fumarate (KF), bimatoprost (BIM), and latanoprost (LN)) revealed a strong correlation between the model drug\'s hydrophobicity and the duration of drug release. Changing the drug loading of the more hydrophilic model drugs, BIM and KF, showed no impact on the drug release kinetics of DECLs loaded with BIM and KF. However, for the hydrophobic model drug, LN, the highest LN loading led to the most extended drug release. The conventional steam sterilisation method was found to damage the PLGA coating on the DECLs fabricated by nES. An alternative sterilisation strategy, such as radiation sterilisation may need to be investigated in the future study to minimise potential harm to the coating.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:经皮给药是一种提高局部药物疗效的新型治疗技术。
    目的:在这项临床试验中,我们评估了二氧化碳分数(FCO2)激光和比马前列素溶液联合治疗斑秃与单用比马前列素治疗的疗效。
    方法:这是一项针对20例斑秃患者的前瞻性患者比较随机临床试验。在每个参与者中,选择两个贴片随机接受局部0.03%比马前列素溶液(每天两次,持续12周)或与FCO2激光组合(每2周,持续12周)。然后通过测量脱发工具评分系统(SALT)评分的严重程度来评估对治疗的反应,头发再生的百分比,医生评估和患者满意度。
    结果:两个治疗组的SALT评分在治疗期间和随访3个月后均显著降低(p=0.000)。在研究结束时,联合治疗和单一治疗组的SALT评分改善的平均百分比分别为46.43±4.35%和21.16±4.06%,在随访期结束时分别为46.42±5.75%和16.11±3.10%。分别为(p=0.000)。双向分析的一般线性模型表明,在一段时间内,联合治疗组的结果明显优于单一治疗组(F1.6,13.2=43.8。p=0.000)。
    结论:分段消融激光可被认为是提高局部药物疗效的辅助方法,尤其是在斑片状斑秃的难治性病例中。
    BACKGROUND: Transepidermal drug delivery is a novel therapeutic technique to boost efficacy of topical drugs.
    OBJECTIVE: In this clinical trial we evaluate the efficacy of the combination of fractional carbon dioxide (FCO2) laser and bimatoprost solution compared to bimatoprost alone in the treatment of alopecia areata.
    METHODS: This is a prospective intra-patient comparative randomized clinical trial on 20 patients with alopecia areata. In each participant two patches were chosen to randomly receive either topical 0.03% bimatoprost solution (twice a day for 12 weeks) alone or in combination with FCO2 laser (every 2 weeks for 12 weeks). Then response to treatment was evaluated by the measurement of the severity of alopecia tool score system (SALT) score, percentage of hair regrowth, physician assessment and patients\' satisfaction.
    RESULTS: SALT score was reduced significantly during treatment sessions and after a 3-month follow-up in both treatment groups (p = 0.000). The mean percentage of improvement in SALT score in the combination therapy and monotherapy groups were 46.43 ± 4.35% and 21.16 ± 4.06% at the end of the study and 46.42 ± 5.75% and16.11 ± 3.10% at the end of the follow-up period, respectively (p = 0.000). A general linear model of two-way analysis demonstrated a significantly superior outcome in the combination therapy group compared to the monotherapy group during time (F1.6, 13.2 = 43.8. p = 0.000).
    CONCLUSIONS: Fractional ablative laser can be considered as an assistant method for enhancing of efficacy of topical drugs especially in refractory cases of patchy alopecia areata.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号